Although BCR-ABL þ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease. Besides cytotoxic T cells, natural killer (NK) cells may have a role in immune control of CML. Here, we explored the functionality of NK cells in CML patients and in a transgenic inducible BCR-ABL mouse model. Compared with controls, NK-cell proportions among lymphocytes were decreased at diagnosis of CML and did not recover during imatinib-induced remission for 10-34 months. Functional experiments revealed limited in vitro expansion of NK cells from CML patients and a reduced degranulation response to K562 target cells both at diagnosis and during imatinib therapy. Consistent with the results in human CML, relative numbers of NK1.1 þ NK cells were reduced following induction of BCR-ABL expression in mice, and the defects persisted after BCR-ABL reversion. Moreover, target-induced degranulation by expanded BCR-ABL þ NK cells was compromised. We conclude that CML is associated with quantitative and functional defects within the NK-cell compartment, which is reproduced by induced BCR-ABL expression in mice. Further work will aim at identifying the mechanisms of NK-cell deficiency in CML and at developing strategies to exploit NK cells for immunotherapy.
Introduction
On the basis of the critical role of BCR-ABL kinase activity in chronic myeloid leukemia (CML), 1,2 tyrosine kinase inhibitors (TKIs) have become the first-line treatment for chronic phase disease. [3] [4] [5] [6] Although targeted pharmacotherapy effectively induces and sustains remissions, molecular disease often persists, [5] [6] [7] and TKIs can be discontinued without relapse only in a subset of patients. 8 Indeed, primitive quiescent leukemic stem cells resist elimination by TKIs [9] [10] [11] [12] and thus represent a potential source of disease progression. In contrast to TKIs, allogeneic hematopoietic stem cell transplantation can eradicate the disease in most patients. 13 This effect is mainly attributed to graft-versus-leukemia reactions, as illustrated by the remarkable efficacy of donor lymphocyte infusions in re-inducing durable responses in relapsed disease.
14 Besides cytotoxic T cells, natural killer (NK) cells have been implicated in immunologic control of CML. [15] [16] [17] In vitro studies have demonstrated at least moderate lysis of hematopoietic progenitor cells from CML patients, including the quiescent CD34 þ sub-population, by allogeneic NK cells. 18, 19 Importantly, killer-cell immunoglobulin-like receptor incompatibility was not essential for NK-cell-mediated anti-leukemic effects in CML, 19 and autologous activated NK cells were able to efficiently suppress the growth of malignant hematopoietic progenitors in vitro. 20, 21 Moreover, in a recent clinical trial evaluating the persistence of remission after stopping imatinib, higher peripheral NK-cell counts were associated with a reduced risk of relapse. 22 These observations raise the question why autologous NK cells in CML are unable to prevent leukemogenesis or eliminate residual disease.
Although the majority of autologous NK cells in chronic phase CML are not derived from the malignant clone, 23, 24 some studies report that NK cells from CML patients are reduced in numbers and have limited cytolytic capacity. 25, 26 These studies were performed during disease progression before the introduction of imatinib, and patients had been pre-treated with hydroxyurea. NK-cell function in untreated patients with chronic phase CML has not been systematically addressed. Furthermore, treatment with TKIs may have additional effects on cellular immune function. Complex immune interactions have been shown for the broad-spectrum kinase inhibitor dasatinib, including both immunosuppressive and promotive effects on T-cell and NK-cell functions. [27] [28] [29] Imatinib was shown to inhibit T-cell functions 30, 31 but not NK-cell cytotoxicity and cytokine secretion. 29 Importantly, despite the immunosuppressive activities reported for both drugs in vitro, functional T-cell responses were reported to develop in CML patients on imatinib, [32] [33] [34] and clonal lymphoproliferation was observed in some patients on dasatinib and was associated with favorable clinical responses. [35] [36] [37] [38] Thus, further in vivo studies are needed to discern the effects of TKIs on immune effector cells.
Here, we report that NK cells of patients with newly diagnosed CML have profound quantitative and functional defects, and that these abnormalities persist during imatinibinduced remission. Mice with CML-like myeloproliferation induced by BCR-ABL expression in HSCs had similar alterations within their NK-cell subset. Together, our results support a role of aberrant tyrosine kinase activity in NK-cell dysfunction in CML, which can only partially be rescued by TKI treatment. 
Patients and methods

Patients and healthy donors
Inducible transgenic BCR-ABL þ mouse model
The generation of the tet-off inducible transgenic mouse strain SCLtTAxBCR-ABL was described previously. 2 Briefly, the transactivator protein tTA was placed under the control of the murine stem cell leukemia (SCL) gene 3 0 enhancer. Crossbreeding of SCLtTA mice with TRE-BCR-ABL mice 39 allowed for inducible expression of P210 BCR-ABL in hematopoietic stem and progenitor cells. 2 To confirm myeloproliferative disease after induction of BCR-ABL, spleen and bone marrow (BM) cells were analyzed by white blood cell counts and differentials.
2 Animal research was approved by the local authorities of North Rhine-Westphalia.
Flow cytometry
For analysis of human lymphocytes, peripheral blood mononuclear cells (PBMC) were purified by density gradient centrifugation, resuspended in RPMI 1640 medium (Invitrogen, Darmstadt, Germany), supplemented with 10% fetal calf serum and 2 mM L-glutamine (RPMI culture medium). PBMCs were stained with fluorescence-labeled anti-human antibodies against the following molecules: CD3, CD4, CD8, CD19, CD56, CD16, NKG2D, NKG2A, NKG2C and CD94 for 30 min at room temperature. All antibodies were from BD Biosciences, Heidelberg, Germany. Cells were analyzed using a FACSCanto or FACSAria cytometer (BD Biosciences). For immunophenotyping of murine lymphocytes, BM and spleen cells were isolated as described previously 2 and stained with fluorescence-conjugated antibodies against murine CD45/B220, CD3, CD4, CD8 and NK1.1 for 30 min at room temperature.
Real-time quantitative reversed-transcribed PCR
NK cells were negatively selected from spleen and BM cells using the NK-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany), and RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany), followed by complementary DNA synthesis using the Moloney murine leukemia virus reverse transcriptase from Promega (Mannheim, Germany). For detection of p210 BCR-ABL transcripts, a real-time TaqMan assay (Eurogentec, Cologne, Germany) and PCR master (TaqMan Universal PCR Master Mix, Applied Biosystems, Weiterstadt, Germany) were used in combination with the ABI 7500 Fast Real-time PCR system (Applied Biosystems), as described previously. 12 As an internal standard, the expression level of glyceraldehyde-3-phosphate dehydrogenase was used.
In vitro expansion of NK cells
For expansion of human NK cells, PBMCs were incubated at 1 Â 10 6 per well in 24-well tissue-culture plates in the presence of 40 IU/ml recombinant human IL-2 (Proleukin, Chiron, Emeryville, CA, USA) in RPMI culture medium and stimulated once with 0.75 Â 10 6 irradiated (120 Gy) K562-mb15-41BBL stimulator cells for 10 days, as described by Dario Campana's group. 40 To expand murine NK cells, purified NK cells were incubated in 24-well tissue-culture plates at 2 Â 10 6 per well in RPMI culture medium, supplemented with 25 IU/ml of recombinant murine interleukin-2 (Immunotools, Friesoythe, Germany). Cells were cultured for 14 days with medium changes every 2 days.
CD107a assay
Degranulation responses were assessed by flow cytometric analysis of CD107a expression after 4-h coincubation with NK-cell-sensitive target cells. For murine NK cells, YAC-1/NIH-3T3 (kind gift by A Johannsen, Lausanne, Switzerland) was used as target cell lines, while human NK cells were tested against K562 cells (ATCC, Manassas, VA, USA). The murine myoblast cell line C2C12 (kind gift by A Santel, Berlin, Germany), and the human myeloid ML-2 cell line (ATCC) were used as control targets. Coincubations were performed at a 1:1 stimulator to responder ratio in the presence of phycoerythrin-labeled antimurine or anti-human CD107a antibody (BD Biosciences), respectively, and 2 mM monensin (Sigma, Munich, Germany). After washing, NK cells were stained with anti-mouse NK1.1-PE-Cy7 and CD3-AF647, or anti-human CD56-PE-Cy7 and CD3-FITC antibodies, respectively, followed by flow cytometric analysis. 
Cytotoxicity assays
mCi
51
Cr/1 Â 10 6 cells (phycoerythrin Applied Biosystems) in a total volume of 200 ml in a V-bottomed 96-well plate at 37 1C and 5% CO 2 . Supernatants were harvested and radioactivity was counted in a gamma counter. Maximum release was determined by target cell lysis with Triton X.
Statistics
Data were analyzed descriptively using Box-and-Whisker plots. The box corresponds to the 25th/75th percentile. Whiskers were drawn from the ends of the box to the 5th and 95th percentile of data values. The Mann-Whitney U-test was used to test whether the medians in each set of values differ significantly. A P-value o0.05 was considered statistically significant. All statistical analyses are intended to be exploratory and not confirmatory. No adjustment for multiple testing was carried out. Statistical analyses were performed using PASW Statistics 18 for Windows (SPSS Inc., Chicago, IL, USA).
Results
NK cells are reduced among lymphocytes in patients with CML and do not recover with imatinib treatment
Forty patients with CML were included into the study (Supplementary Table 1 ). Median age was 49 years (range 9-68 years), and median white blood cell count at diagnosis was 76 500/ml (range 5000-554 000/ml). All patients were treated with imatinib at 400-800 mg/days. In all, 31 of 36 evaluable patients achieved major or complete molecular responses that were sustained under continuous imatinib treatment for up to 96 months of follow-up, and 5 patients achieved partial or complete cytogenetic responses. Blood samples from 36 healthy controls (median age 45 years, 24-77 years) were used as controls.
To investigate the peripheral lymphocyte compartment in CML, individual sub-populations were quantified among peripheral blood lymphocytes by flow cytometry. Relative numbers of CD3 þ T cells, CD8 þ T cells, CD4 þ T cells and B cells did not significantly differ between newly diagnosed patients and healthy controls, and no significant differences were found between pre-treatment and remission samples ( Figure 1a) . However, the relative proportions of CD3ÀCD56 þ NK cells in patients with CML before treatment were significantly reduced compared with controls (median 5.1%, range 2.7-12.6% vs 11.0%, range 3.0-19.8%) (P ¼ 0.002). Repeated analysis in remission samples on imatinib treatment demonstrated a persistent decrease in NK-cell proportions among total lymphocytes (median 8.1%, range 2.1-16.0%, P ¼ 0.003) ( Figure 1a ).
Longitudinal analysis was performed in nine patients who were selected from our cohort for the availability of at least three follow-up samples during imatinib-induced remission. The relative NK-cell numbers among lymphocytes remained below normal controls in the majority of samples, without any trend to recover during up to 34 months of remission ( Figure 1b) . Next, we investigated whether the numerical impairment of the NK-cell compartment in CML was accompanied by phenotypic alterations. By surface expression of CD16, NK cells can be subclassified into the predominant CD56lowCD16hi NK-cell subset representing a highly cytolytic NK-cell subpopulation, and cytokine-producing CD56hiCD16low NK cells. 41 No differences regarding the relative proportions of CD56lowCD16hi and CD56hiCD16low NK-cell subsets were found between pre-treatment and remission samples compared with controls (Figure 2a ). Activating receptors on NK cells, for example, NKG2D, can overcome inhibitory signals and have been implicated in anti-leukemic effects in CML. 19 The proportions of NKG2D-expressing cells among NK cells were comparable between CML patients at diagnosis and controls (Figure 2b) . Moreover, the proportions of NK cells expressing the inhibitory receptor CD94/NKG2A or the activating receptor CD94/NKG2C did not vary between patients and controls. By contrast, NKG2D expression was significantly downregulated in patients on imatinib compared with both healthy controls (P ¼ 0.003) and at diagnosis (P ¼ 0.02).
NK cells in CML patients are functionally impaired both at diagnosis and during imatinib treatment
To address the functionality of NK cells in CML, we investigated their capacity to expand after in vitro stimulation and to release cytolytic granules in response to NK-cell-sensitive targets. Stimulation of PBMCs with irradiated K562 cells gene-modified to express membrane-bound IL-15 and 41BB ligand in the presence of low-dose (40 IU/ml) recombinant human IL-2 has been found to induce efficient and selective NK-cell expansion from the peripheral blood of both healthy donors 40 and patients in remission of acute leukemia. 42 In vitro stimulation with irradiated K562-mb15-4 1BBL at a 0.75:1 ratio, followed by 10-day in vitro expansion in the presence of recombinant human IL-2 (40 IU/ml) resulted in a median 37-fold (8-64-fold) increase in CD3ÀCD56 þ NK cells in healthy donors and a median purity of 94% (92-96%) CD3ÀCD56 þ NK cells within the stimulated bulk populations (Figure 3a) . Absolute median numbers of 4.1 Â 10 6 (0.8-6.4 Â 10 6 ) NK cells were generated from 1 Â 10 6 PBMCs on day 10. By contrast, in five patients with newly diagnosed CML, NK-cell proliferation was substantially reduced, with median 5-fold expansion (range 0-27-fold) and median culture yields of 0.5 Â 10 6 , range 0.0-4.0 Â 10 6 /ml (P ¼ 0.01). Following imatinib treatment, NK-cell expansion to stimulation remained significantly impaired (median 28-fold, range 4-45-fold), with a median NK-cell yield of 2.8 Â 10 6 , range 1.1-5.4 Â 10 6 (P ¼ 0.005) ( Figure 3b ). Next, we investigated whether the failure of NK cells to recover to normal numbers in patients in remission was mediated by negative direct effects of imatinib on NK-cell proliferation. Although high concentrations of imatinib (5 and 10 mM) significantly impaired in vitro NK-cell expansion (Figure 3c ), a dose of 1 mM representing relevant plasma levels in patients under daily imatinib 43 did not significantly affect in vitro proliferation of NK cells from both healthy donors ( Figure 3c ) and CML patients under in vivo imatinib treatment (Figure 3d) . Next, we compared degranulation responses with the NK-cell-sensitive target cell line K562 by CD107a upregulation that provides a sensitive parameter for NK-cell activation. 44 As expected, coincubation of NK cells expanded from healthy donors with K562 cells resulted in potent degranulation responses with a median of 21.0% (9.8-33.0%) CD107a-expressing cells within the CD3ÀCD56 þ NK-cell gate, whereas the NK-cell-resistant leukemia cell line ML-2 failed to induce NK-cell activation (Figures 4a and b) . By contrast, NK cells expanded from patients with newly diagnosed CML had significantly lower degranulation responses (median 1.0%, range 0.0-6.6%, P ¼ 0.02) and these did not return to normal levels in remission under treatment with imatinib (median 9.6%, range 3.6-45.6%, P ¼ 0.026). To rule out that the absence of imatinib during in vitro expansion may have allowed NK cells from CML patients to partially restore functionality, we further analyzed NK cells expanded in the presence of imatinib.
Comparable results were obtained regardless of the presence or absence of 1 mM imatinib in the culture medium during expansion (Figure 4b, left and center panel) . Moreover, to exclude that the functional deficits are a consequence of in vitro NK-cell stimulation and expansion, we reproduced the experiments with NK cells directly isolated from peripheral blood. Although the degranulation responses by non-expanded NK cells were generally higher, significantly reduced CD107a secretion was again found in CML patients compared with healthy donors (Figure 4b, right panel) . No significant correlation of CD107a secretion with disease response at the time of analysis was found (Figure 4c) . In contrast to the reduced degranulation responses, direct cytolysis of K562 by 51 Cr release was unaffected at various effector to target ratios in patients on imatinib treatment (Figure 4d, Supplementary  Figure 2 ). Again, presence or absence of 1 mM imatinib in the culture medium during NK-cell expansion did not affect results ( Figure 4d , center panel), and non-expanded NK cells from healthy donors and patients were also equally effective (Figure 4d, right panel) . Thus, NK cells from CML patients both at diagnosis and under treatment with imatinib have significantly decreased degranulation responses, and in vitro expansion fails to restore full functionality. In these experiments using the highly NK-cell-sensitive target K562, decreased degranulation by CD107a secretion does not translate into impaired direct cytolysis.
BCR-ABL expression in murine hematopoetic cells decreases NK-cell proportions within the lymphoid compartment
To investigate whether the defective NK-cell compartment in CML is a consequence of the BCR-ABL-induced myeloproliferation that characterizes the disease, we addressed the quantity and functionality of NK cells in a double transgenic mouse model of human CML. 2, 12 SCLtTA/BCR-ABL transgenic mice inducibly and reversibly express BCR-ABL under the control of the 3 0 enhancer of the murine SCL gene. 2, 12 Within 4 weeks of induction of BCR-ABL, all mice (n ¼ 11) developed a chronicphase CML-like disease including splenomegaly (median 335 mg vs 108 mg in BCR-ABL-negative control mice, P ¼ 0.001) and neutrophilia in BM and spleen (not shown). Spleen weight further increased to a median of 544 mg (P ¼ 0.001) during prolonged BCR-ABL induction of a total of 8 weeks. After re-administration of tetracycline, the CML-like phenotype was completely reverted (median spleen weight 129 mg, P ¼ 0.14 in comparison with non-induced control mice). Thus, this model indeed allows to directly address the role of aberrant BCR-ABL expression in hematopoietic stem cells on the murine NK-cell compartment. Owing to the limited total numbers of NK cells that can be recovered from the peripheral blood of these mice, we focused on splenic and BM NK cells. BCR-ABL expression was induced in 14 mice by withdrawal of tetracycline, while 14 mice continued to receive tetracycline and served as controls. Contrary to human CML, 23, 24, 45 NK cells from all BCR-ABL þ mice expressed the BCR-ABL transcript.
Splenic lymphocyte sub-populations in BCR-ABL-negative and BCR-ABL-induced mice were compared by flow cytometry. The relative proportions of CD3 þ T cells, CD4 þ T cells, CD8 þ T cells and B cells were not different after BCR-ABL induction compared with BCR-ABL-negative controls ( Figure 5 ). By contrast, consistent with the results in human CML, the relative proportions of NK1.1 þ NK cells among total splenic lymphocytes were significantly reduced in BCR-ABL-induced mice after 4 and 8 weeks (2.3-9.8% (median 7,1%), and 2.6-10.4% (median 8.4%), vs 9.7-16.9% (median 14.8%) in healthy controls, P ¼ 0.02 and P ¼ 0.01) ( Figure 5 ). Following reversion of BCR-ABL expression, splenic NK-cell numbers remained at levels detected in BCR-ABL þ mice. Alterations within the lymphocyte compartment in BCR-ABL reverted mice also involved T-and B-lymphocytes. As a consequence of increased proportions of CD4 þ and CD8 þ T cells and significantly decreased numbers of B cells, the T-to B-cell ratio was significantly increased in BCR-ABL reverted mice ( Figure 5 ).
BCR-ABL expression decreases degranulation responses of murine NK cells
To assess the proliferative and functional properties of NK cells from BCR-ABL þ mice, NK cells were negatively selected from splenic lymphocytes, resulting in purities of 93% (89-97%) NK1.1 þ NK cells. Purified NK cells were cultured in the presence of IL-2 under conditions previously shown to induce potent in vitro proliferation of murine NK cells. 46 In contrast to the limited in vitro expansion rates of human NK cells (Figure 3b ), splenic NK1.1 þ NK cells from BCR-ABL þ mice and control mice expanded at equal rates during 14-day cultures (Figure 6a) . These experiments were reproduced with NK cells from murine BM, and again demonstrated comparable expansion rates between BCR-ABL þ and control mice (Figure 7a ). During expansion, the purities of both experimental and control cultures were maintained at 96.5% (90-97%) and 95% (89-97%) NK cells, respectively. Analogous to our experiments with human CML NK cells (Figures 4a and b) , the degranulation response to coincubation with the NK-cell-sensitive target cell lines YAC-1/NIH-3T3 was assessed as a parameter for NK-cell activation. NK cells expanded from purified populations of splenic and BM NK cells were used for these experiments. To exclude non-NK lymphocytes from analysis, the gate was set on NK1.1 þ CD3-negative cells (Figure 6b ). Background degranulation in response to C2C12 control target cells (Figure 6c ) was subtracted for each sample. Compared with NK cells isolated and expanded from BCR-ABL-negative control mice, the degranulation response of splenic NK cells from BCR-ABL þ mice after 4 and 8 weeks of induction to YAC-1/NIH-3T3 cells was significantly decreased (median 30.1% (2.0-31.2%) and 22.1% (20.5-30.1%) vs 38.6% (20.7-50.0%) in healthy controls, P ¼ 0.008 and P ¼ 0.007) (Figure 6d ). Analogous results were obtained with NK cells expanded from BM of BCR-ABL þ and control mice (Figure 7b) . Thus, BCR-ABL expression in the hematopoietic cell compartment results in numerical reduction and functional impairment of NK cells. control the malignant clone. Initial reports of deficient NK-cell function in CML 45, 49 were confounded by previous chemotherapy or interferon-a, which can exert long-acting effects on the immune system, and by the advanced disease status in many patients. Here, we demonstrate that untreated patients with newly diagnosed chronic or accelerated-phase CML have both reduced NK-cell numbers and functionally defective NK cells. Functional impairment includes reduced in vitro proliferation in response to stimulation and impaired degranulation responses to NK-cell-sensitive target cells. Our observation that direct cytolysis of K562 cells was unimpaired despite reduced degranulation by CD107a secretion may be explained by the extraordinary sensitivity of this cell line toward NK-cell lysis. Although the detailed functional profile of CML NK cells will have to be addressed in future studies including autologous CML target cells, our data provide strong evidence that the NK-cell compartment in CML is altered both by the disease itself and by imatinib treatment.
Discussion
One potential explanation for dysfunctional NK cells in CML is their exposure to the malignant environment that includes cellular products or negative signals by BCR-ABL þ CML cells. It has been hypothesized that reactive oxygen species produced by circulating clonal granulocytes trigger NK-cell apoptosis, however, CML cells did not constitutively inhibit NK cells in vitro. 50 Alternatively, BCR-ABL þ cells within the hematopoietic cell compartment may negatively and selectively affect differentiation of non-malignant progenitors toward NK cells. 45 In vitro coincubation assays cannot adequately mimic these interactions. Therefore, to investigate the role of the malignant CML microenvironment on NK-cell deficiency in vivo, we used an inducible murine model that reflects CML-like myeloproliferation by BCR-ABL kinase activity in hematopoetic stem cells. 23 The strength of this model is that it closely simulates in vivo conditions in CML patients along with control populations only differing by the lack of BCR-ABL expression. Moreover, reversion of BCR-ABL allows to mimic complete remissions. Indeed, analogous to our findings in CML patients, NK cells from mice with CML-like disease following induction of BCR-ABL expression were reduced in numbers and exhibited defective degranulation responses. This confirms that BCR-ABL kinase expression in the hematopoetic compartment has profound effects on the generation and function of NK cells. Remarkably, in both human CML and the murine model, the NK-cell compartment was selectively affected, while T-and B-cell numbers were comparable to healthy donors and BCR-ABL-negative mice, respectively. Despite the similarities between BCR-ABL-induced mice and CML patients, interpretation of the results requires consideration of several caveats. First, the clonal origins of NK cells from either BCR-ABL-positive or -negative hematopoietic stem cells may significantly affect the results. The majority of human NK cells in chronic phase CML are not derived from the malignant clone. 23, 24, 45 By contrast, despite the close resemblance of the myeloproliferative phenotype of BCR-ABL-induced SCLtTAxBCR-ABL mice with human disease, expression of the transgene under the murine SCL gene 3 0 enhancer in mice includes the NK-cell compartment. Thus, while aberrant kinase activity within the NK-cell subset fails to explain the deficits observed in human CML, it may have contributed to the impairment of NK cells in BCR-ABL þ mice.
Second, the splenic and BM origin of NK cells in the mouse model may not be representative of the peripheral NK-cell compartment in humans. Difficulties in obtaining adequate NK-cell numbers from murine peripheral blood and limited availability of BM from CML patients precluded direct comparisons of the respective compartments. However, the remarkable similarities between our findings in splenic and BM lymphocytes in mice suggest that the impact of the source of NK cells is limited.
Another concern is that in vitro expansion of NK cells to obtain adequate cell numbers for functional experiments may have confounded the results. Indeed, gene expression profiles were shown to undergo substantial changes during NK-cell in vitro expansion. 51 However, comparative functional experiments with non-expanded versus expanded NK cells from some healthy donors and CML patients confirmed the results obtained with expanded NK cells and argue against a major effect of in vitro expansion on NK-cell functionality.
Over previous reports on cellular immune dysfunction in CML, the introduction of TKIs into the treatment has added another level of complexity. There is a striking discrepancy between the predominant immunosuppressive effects of imatinib in vitro, 30, 31 and the development of functional T-cell responses in CML patients treated with this drug. [32] [33] [34] Moreover, the mechanisms underlying the clinically relevant clonal lymphoproliferation in some patients under dasatinib are unresolved. [35] [36] [37] [38] Thus, the in vivo immune effects of TKIs in CML deserve further study. Longitudinal analysis of lymphocyte sub-populations in CML patients on imatinib was subject to one previous report. 52 An immunoprofile resembling that of healthy controls was found to be re-established on imatinib, however, the NK-cell compartment was not analyzed in detail. Here, we show that imatinib treatment fails to restore the full functionality of CML NK cells. NK cells remained reduced in numbers, and their in vitro proliferative and granule secretion responses to a potent activation stimulus did not recover. Moreover, expression of the NKG2D receptor was downregulated during imatinibinduced remissions. Decreased NKG2D expression on NK cells was associated with impaired NK-cell function in cancer patients 53 and may thus be involved in immune escape. Impaired degranulation was detected both by native NK cells and after previous expansion either in the presence or absence of imatinib, thus it cannot be compensated by a potent activation stimulus outside the imatinib-containing microenvironment. Thus, defects of hematopoietic precursor cells induced by the leukemic clone may persist even after elimination of the majority of BCR-ABL þ cells. Alternatively or additionally, inhibition of off-target kinases in immune effector cells by imatinib may induce similar alterations to the malignant environment.
In mice, reverting BCR-ABL failed to reconstitute normal NK-cell numbers in control mice and thus mimicked the persistent alterations observed in human CML on imatinib. This indeed suggests that disturbance of the immune cell compartment in the presence of the malignant clone may persist beyond remission. However, lymphocyte sub-populations underwent even more profound changes by BCR-ABL reversion, now involving T and B cells that were not observed in the human system. Thus again, the capacity of the murine model to fully reflect the human disease must be considered with caution.
Augmenting autologous NK-cell responses may be an efficient treatment strategy in minimal residual disease in CML. In fact, in a pilot clinical trial evaluating the persistence of complete molecular remission after stopping imatinib, lower peripheral NK-cell counts before imatinib discontinuation were reported as a risk factor significantly associated with subsequent relapse. 22 Importantly, human leukocyte antigen-identical NK cells target not only dividing CML cells, but also quiescent CD34 þ hematopoietic progenitor sub-populations of the leukemic clone, and sensitivity of this critical sub-population to lysis can be increased by bortezomib treatment. 18 Advantages over T-cell-based strategies are the lack of concurrent toxicity because of graft-versus-host disease and of the need to identify leukemia-specific antigens. Importantly, IL-2-containing culture conditions allow for efficient purging of BCR-ABL-positive progenitors 54 and thus help to avoid the risks of leukemia cell contamination of autologous products.
Unfortunately, the profound functional defects that persist throughout imatinib treatment are likely to seriously compromise the anti-leukemic activity of autologous NK-cell transfusions. Indeed, previous attempts at using autologous activated NK cells have failed to prevent relapse after autologous stem cell transplantation. 55 We show here that even optimized stimulatory and cytokine conditions that induce NK cells with potent cytolytic responses to both AML 56 and solid tumors 57 could by themselves not overcome the functional NK-cell defects in CML. More refined strategies to improve the functionality of autologous NK cells in CML are required. Alternatively, adoptive transfer of in vitro expanded allogeneic NK cells remains an option to induce and increase graft-versus-leukemia effects in CML without risking graft-versus-host disease. 18 Identifying the mechanisms of NK-cell deficiency in CML and the detailed interactions of individual TKIs with immune subsets and their crosstalk may help to identify drugs or combination strategies that support therapeutic autologous NK-cell responses.
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